Stocks in Action USA: Viking Therapeutics, Vicor, GameStop
Reading Time: 4 minutes
Viking Therapeutics (VKTX) – VK2735 achieves up to 19% weight loss and emerges as a new challenger for Lilly and Novo! Viking Therapeutics is causing a stir in the market with strong clinical data around its obesity candidate VK2735, which surged by over 30% at times, while established competitors Eli Lilly and Novo Nordisk faced pressure. VK2735 is a dual GLP-1/GIP agonist, which makes it mechanistically closely related to Lilly's Tirzepatide-based treatments Zepbound and Mounjaro; in the recent study, participants lost between 16% and 19%...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
